| Catalog No | Package | Original Price | Price | Inventory | Quantity | Operating |
|---|---|---|---|---|---|---|
| BP5120-5mg | 5mg | $350.00 | Sign in |
|
Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
With the continuous rise in the incidence of neurodegenerative diseases, finding natural products with neuroprotective effects has become an important direction for drug development. Natural products, due to their structural diversity and rich bioactivity, have become a treasure trove for exploring novel neuroprotective agents. 7'R,8'R-2,2'-Dimethoxy-4-3-(3-hydroxypropyl)-4'-(1,2,3-trihydroxypropyl)biphenyl ether (hereinafter referred to as 7'R,8'R-dimethoxydiphenyl ether, CAS No. 515813-60-2) is a natural product with potential neuroprotective activity. This paper aims to systematically review the chemical structure, physicochemical properties, plant origin, pharmacological activity, mechanism of action, druggability evaluation, and clinical application prospects of this compound, hoping to provide reference for related research.
7'R,8'R-Dimethoxydiphenyl ether is a biphenyl ether class of compounds with a molecular formula of C20H24O7 and a molecular weight of 376.4050. Its structural features include two benzene rings connected by ether bonds, with methoxy substituents at positions 2 and 2', and 3-hydroxypropyl and 1,2,3-trihydroxypropyl side chains attached at positions 4 and 4', respectively. The compound's stereochemical configurations are 7'R and 8'R, indicating that it has specific conformations at key chiral centers, which contribute to its biological activity.
In terms of physicochemical properties, the compound has a LogP value of 1.4992, indicating moderate lipid solubility, which facilitates membrane penetration but is not prone to excessive hydrophobicity, balancing solubility and membrane permeability. The topological pole surface area (TPSA) is 108.61 Ų, indicating high polarity that may affect its ability to cross the blood-brain barrier. Its water solubility is 1.1194, indicating a certain solubility in water, which is beneficial for absorption and distribution in the body. The low permeability of the blood-brain barrier suggests that this compound may have difficulty directly entering the central nervous system, but its neuroprotective effects may be achieved through indirect mechanisms or local action. The hERG suppression test results were negative, indicating a low risk of cardiotoxicity. The Ames mutagenic assay result was 0.0, indicating that this compound has no obvious genotoxicity.
7'R,8'R-Dimethoxydiphenyl ether is mainly found in certain traditional Chinese medicinal plants, especially plant genera rich in biphenyl ether compounds, such as certain Magnoliaceae and Lauraceae plants. Specific plant species and their distribution still require further systematic reporting, but existing studies show that this compound is mostly synthesized by secondary plant metabolic pathways as part of plant defense mechanisms.
The extraction method typically uses solvent extraction combined with chromatography separation technology. Common solvents include ethanol, methanol, and their aqueous solutions to ensure effective dissolution of moderately polar 7'R,8'R-dimethoxydiphenyl ethers. The extraction process generally includes drying and crushing of plant materials, solvent extraction, filtrate concentration, and multi-stage column chromatography purification. High-performance liquid chromatography (HPLC) and mass spectrometry (LC-MS) are widely used for qualitative and quantitative analysis of this compound, ensuring the accuracy of its purity and structural identification.
The pharmacological activity of 7'R,8'R-dimethoxybiphenyl ethers is mainly concentrated in the neuroprotective field. Both in vitro and in vivo studies have shown that it has significant neuroprotective effects, reducing nerve cell damage, suppressing neuroinflammatory responses, regulating oxidative stress levels, and improving neurological dysfunction.
Antioxidant effects
This compound enhances intracellular antioxidant enzyme expression by activating the nuclear factor red-related factor 2 (NRF2) signaling pathway, lowering reactive oxygen species (ROS) levels, and alleviating damage to nerve cells caused by oxidative stress.
Anti-inflammatory effects
7'R,8'R-Dimetoxybiphenyl ether can inhibit the release of pro-inflammatory cytokines, reduce neuroinflammatory responses, and protect neurons from inflammation-mediated damage.
Inhibits apoptosis of nerve cells
By regulating the expression of BCL2 family proteins (such as BCL2 and CASP3), it promotes anti-apoptotic signaling, inhibits apoptotic pathways, and maintains neuronal survival.
Improves neurotransmitter metabolism
This compound has a certain inhibitory effect on acetylcholinesterase (ACHE), helping to increase acetylcholine levels and improve cognitive function.
Regulates neuroprotein metabolism
It regulates key neurodegenerative proteins such as amyloid precursor protein (APP), β-secretase (BACE1), and microtubule-associated protein tau (MAPT), helping to slow down the pathological progression of diseases like Alzheimer's.
The neuroprotective effects of 7'R,8'R-dimethoxybiphenyl ether involve multiple signaling pathways and key molecular targets, mainly including:
BCL2 and CASP3: This compound reduces neuronal apoptosis and maintains neuronal survival by upregulating the expression of the anti-apoptotic protein BCL2 and inhibiting the activity of the apoptotic protease CASP3.
APP and BACE1: By inhibiting BACE1 activity, it reduces abnormal APP lysis, lowers β-amyloid protein production, alleviates amyloid plaque deposition, and delays the pathological progression of Alzheimer's disease.
MAPT (tau protein): Regulates abnormal phosphorylation of tau protein, prevents nerve fiber tangles, and protects the structural integrity of nerve cells.
SIRT1: Activates the deacetylating enzyme SIRT1, promotes cellular metabolic homeostasis and antioxidant capacity, and delays neuronal aging.
MAPK1: Regulates the mitogen-activated protein kinase (MAPK) signaling pathway, modulating cellular stress responses and survival signals.
ACHE: Inhibits acetylcholinesterase activity, increases acetylcholine concentration, and improves neurotransmitter function.
SNCA (α-synuclein): regulates the aggregation state of α-synuclein, reducing neurotoxicity associated with Parkinson's disease.
NRF2: Activates the NRF2 signaling pathway, enhances antioxidant enzyme expression, and resists oxidative stress damage.
Overall, 7'R,8'R-dimethoxybiphenyl ether exerts its neuroprotective effects through multi-target and multi-pathway synergistic effects, showing strong therapeutic potential.
Druggability evaluation is a key step in the development of natural product drugs. The molecular weight of 7'R,8'R-dimethoxybiphenyl ether is 376.4050, meeting the Lipinski rule requirement for molecular weight less than 500. The LogP is 1.4992, indicating moderate lipid solubility, which is beneficial for oral absorption. The TPSA was 108.61 Ų, slightly above the ideal threshold of 90 Ų, which may limit its ability to cross the blood-brain barrier, consistent with the observations of low blood-brain barrier permeability observed in the experiment.
Moderate water solubility (1.1194), which helps absorption and distribution in the body. The hERG channel inhibition test was negative, indicating a low risk of cardiotoxicity. The Ames test result was 0, indicating no mutagenicity and good safety.
Pharmacokinetics, although systematic in vivo metabolic and kinetic data are currently lacking, combined with its physicochemical properties, this compound may have good oral bioavailability. However, its blood-brain barrier penetration capacity is limited, suggesting that its neuroprotective effect may require enhancing effective concentrations in the central nervous system through improved drug delivery systems or structural modifications.
7'R,8'R-Dimetoxybiphenyl ether, with its multi-target neuroprotective effects, demonstrates the potential for treating neurodegenerative diseases such as Alzheimer's and Parkinson's. Its combined antioxidant, anti-inflammatory, anti-apoptosis, and neuroprotein metabolism regulation effects provide new ideas for multi-target treatment of neurological diseases.
Future research should focus on the following aspects:
Pharmacokinetics and pharmacodynamics research
In-depth analysis of the absorption, distribution, metabolism, and excretion characteristics of this compound in vivo to clarify its effective concentration and time window of action.
Optimized drug delivery systems
To address the drawback of low blood-brain barrier permeability, delivery systems such as nanocarriers and liposomes have been developed to improve the bioavailability of the central nervous system.
Structural optimization and derivative design
Through chemical modification, its physicochemical properties and targeting capabilities are optimized, enhancing efficacy and safety.
Preclinical and clinical research
Systematic toxicological evaluations and animal model validation are being carried out, gradually advancing clinical trials to verify the safety and efficacy of treating neurodegenerative diseases.
Combination medication strategies
Exploring synergistic effects with other neuroprotective drugs to leverage the advantages of multi-target, multi-mechanism integrated treatment.
7'R,8'R-2,2'-dimethoxy-4-3-(3-hydroxypropenyl)-4'-(1,2,3-trihydroxypropyl)biphenyl ether, as a natural product with a unique structure and multiple neuroprotective effects, has demonstrated good pharmacological activity and superior safety. Its multi-target mechanism of action provides new targets and strategies for the treatment of neurodegenerative diseases. In the future, through systematic pharmacokinetic studies, optimized drug delivery, and clinical validation, it is expected to become a novel neuroprotective drug, benefiting a wide range of neurological disease patients.
